NASDAQ$FULC
Fulcrum Therapeutics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Fulcrum Therapeutics reported first quarter 2022 financial results and business highlights.
Fulcrum Therapeutics reported a net loss of $25.9 million for the first quarter of 2022. The company's clinical programs continued to progress, with upcoming milestones including data presentations for FTX-6058 and the initiation of the Phase 3 REACH trial for losmapimod.
- Initial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 Congress.
- Phase 3 REACH trial of losmapimod in FSHD expected to begin in 2Q 2022.
- Cash, cash equivalents, and marketable securities were $195.1 million as of March 31, 2022.
- Collaboration revenue was $2.6 million for the first quarter of 2022.
Headline financials
Revenue & EPS history
Fulcrum Therapeutics · Revenue · Quarterly
$2.59M
Forward guidance
Fulcrum Therapeutics anticipates several milestones, including presenting data from the FTX-6058 trial, initiating the REACH trial, and nominating a new development candidate.
Tailwinds
- Report initial data from the ongoing 6 mg dose cohort in the Phase 1b trial in people with sickle cell disease at the European Hematology Association (EHA) 2022 Hybrid Congress, taking place from June 9-12, 2022.
- Open next dose cohort in Phase 1b trial in people with sickle cell disease in the second quarter of 2022.
- Initiate registrational trial in sickle cell disease in early 2023.
- Initiation of Phase 1b trial in select other hemoglobinopathies, including beta-thalassemia, now expected in the second half of 2022.
- Initiate REACH, a Phase 3 randomized, double-blind, placebo-controlled multi-national trial that will evaluate the efficacy and safety of losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD), in the second quarter of 2022.
Headwinds
- Risks associated with Fulcrum’s ability to continue to advance its product candidates in clinical trials.
- Risks related to initiating and enrolling clinical trials on the timeline expected or at all.
- Risks related to obtaining and maintaining necessary approvals from the FDA and other regulatory authorities.
- Risks related to replicating in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials of losmapimod, FTX-6058 and its other product candidates.
- Risks related to managing expenses and raising the substantial additional capital needed to achieve its business objectives.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+5.2%
Avg return
Earnings day
+6.3%
Avg return
5 days after
+12.3%
Avg return
30 days after
62%
16 / 26 earnings
Positive
+142.5%
Q2 2021
Best reaction
-54.6%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -21.1% | -23.0% | -36.3% | |
| Q3 2025 | -6.6% | -9.8% | +9.4% | |
| Q1 2025 | +13.8% | +39.0% | +78.6% | |
| Q4 2024 | +0.0% | -3.0% | -16.5% | |
| Q3 2024 | -8.8% | -16.8% | +8.8% | |
| Q2 2024 | +7.1% | +0.6% | +1.7% | |
| Q1 2024 | +5.9% | +1.1% | +3.2% | |
| Q4 2023 | +6.1% | +12.9% | -3.0% | |
| Q3 2023 | +16.2% | -2.5% | +38.2% | |
| Q2 2023 | +3.4% | +5.5% | +49.7% | |
| Q1 2023 | +16.2% | -0.6% | -7.6% | |
| Q4 2022 | -28.0% | -36.6% | -62.0% | |
| Q3 2022 | +23.9% | +27.3% | +9.4% | |
| Q2 2022 | +8.4% | -6.2% | +7.1% | |
| Q1 2022 | -12.5% | -4.1% | -3.8% | |
| Q4 2021 | +17.4% | +37.8% | +113.9% | |
| Q3 2021 | -2.3% | -4.9% | -31.5% | |
| Q2 2021 | +142.5% | +175.3% | +233.9% | |
| Q1 2021 | +4.1% | +3.7% | -13.2% | |
| Q4 2020 | -17.7% | -17.4% | -17.8% | |
| Q3 2020 | +8.6% | +16.9% | +22.3% | |
| Q2 2020 | -54.6% | -55.5% | -54.7% | |
| Q1 2020 | +7.9% | +18.9% | +16.5% | |
| Q4 2019 | -2.2% | -27.8% | -49.4% | |
| Q3 2019 | +1.3% | +27.7% | +48.9% | |
| Q2 2019 | +7.2% | +6.1% | -25.5% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro